|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Cansino_Biologics_Inc.
|
|
gptkbp:ceo
|
gptkb:Xiaoming_Yang
|
|
gptkbp:clinical_data
|
vaccine efficacy
|
|
gptkbp:clinical_data_analysis
|
vaccine trials
|
|
gptkbp:clinical_outcomes
|
safety and efficacy
|
|
gptkbp:clinical_partners
|
hospitals
|
|
gptkbp:clinical_phase
|
Phase III
|
|
gptkbp:clinical_trial
|
gptkb:China
gptkb:vaccine
Phase II
vaccine safety
|
|
gptkbp:collaboration
|
gptkb:Astra_Zeneca
vaccine development
|
|
gptkbp:collaborations
|
gptkb:Chinese_Academy_of_Military_Medical_Sciences
international research institutions
|
|
gptkbp:community_engagement
|
health education
|
|
gptkbp:focus
|
vaccine development
|
|
gptkbp:founded
|
gptkb:2009
|
|
gptkbp:has_research_center
|
Tianjin facility
|
|
gptkbp:headquarters
|
gptkb:Tianjin,_China
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Can Sino Biologics
|
|
gptkbp:innovation
|
biotechnology solutions
|
|
gptkbp:invention
|
vaccine technologies
|
|
gptkbp:investment
|
biopharmaceutical industry
|
|
gptkbp:is_vulnerable_to
|
public health
|
|
gptkbp:market
|
gptkb:China
|
|
gptkbp:marketing_strategy
|
vaccine rollout
|
|
gptkbp:notable_products
|
gptkb:Ad5-n_Co_V
|
|
gptkbp:partnership
|
gptkb:National_Research_Council_of_Canada
|
|
gptkbp:partnerships
|
global health organizations
|
|
gptkbp:product_development
|
gptkb:vaccine
|
|
gptkbp:product_line
|
vaccines
|
|
gptkbp:public_health_impact
|
pandemic response
|
|
gptkbp:publication
|
vaccine research
|
|
gptkbp:publicly_traded
|
gptkb:Hong_Kong_Stock_Exchange
|
|
gptkbp:reach
|
international markets
|
|
gptkbp:regulatory_compliance
|
gptkb:China_National_Medical_Products_Administration
international standards
|
|
gptkbp:research_areas
|
infectious diseases
|
|
gptkbp:research_focus
|
immunology
|
|
gptkbp:research_interest
|
vaccine research
|
|
gptkbp:safety_measures
|
clinical trials
|
|
gptkbp:social_responsibility
|
health initiatives
|
|
gptkbp:supply_chain
|
vaccine distribution
|
|
gptkbp:technology
|
viral vector technology
|
|
gptkbp:vaccine_administration
|
healthcare providers
|
|
gptkbp:vaccine_approval
|
emergency use authorization
|
|
gptkbp:vaccine_development_process
|
clinical trials
|
|
gptkbp:vaccine_distribution
|
global supply chain
|
|
gptkbp:vaccine_distribution_network
|
logistics partners
|
|
gptkbp:vaccine_distribution_partners
|
logistics companies
|
|
gptkbp:vaccine_distribution_strategy
|
global health initiatives
|
|
gptkbp:vaccine_education
|
community outreach
|
|
gptkbp:vaccine_implementation
|
healthcare systems
|
|
gptkbp:vaccine_research
|
infectious diseases
|
|
gptkbp:vaccine_research_collaboration
|
academic institutions
|
|
gptkbp:vaccine_research_collaborations
|
international organizations
|
|
gptkbp:vaccine_research_investment
|
government funding
|
|
gptkbp:vaccine_safety_studies
|
clinical research
|
|
gptkbp:vaccine_storage
|
cold chain logistics
|
|
gptkbp:vaccine_technology
|
recombinant technology
|
|
gptkbp:vaccine_technology_advancements
|
gptkb:scientific_research
|
|
gptkbp:vaccine_technology_innovation
|
research grants
|
|
gptkbp:vaccine_technology_partnerships
|
biotech firms
|
|
gptkbp:vaccine_type
|
viral vector vaccine
|
|
gptkbp:bfsParent
|
gptkb:CVn_Co_V
|
|
gptkbp:bfsLayer
|
5
|